The Community

The Trust Engine Behind Every Insight

NOWINCLUDED is Acclinate’s community of 190,000+ members taking action for better health. It is a culturally relevant, always-on engagement ecosystem where people feel seen, supported, and informed.

This is not a database; it is the living source of the signals that power Acclinate’s patented AI/ML engine. Curious about how it works? Click the button below and join the community.

Overview

Built from Trust. Designed for Belonging.

NOWINCLUDED is the foundation of Touch + Tech. It provides:

Longitudinal behavioral insights

Cultural context

Real-time sentiment

Clinical education pathways

A direct connection between community voice and clinical research

This depth cannot be replicated, bought, or recruited on demand.

Features

Your Representation Problem, Solved.

Through culturally relevant engagement and a proven three-stage model, we move individuals from awareness to enrollment — enabling partners meet engagement goals while strengthening long-term brand equity.

An exclusive pool of research-ready participants

Direct access to a continuously growing community of engaged individuals who have opted in to learn about research, share experiences, and participate in studies.

Authenticated demographic and behavioral signals

First-party insights collected through ongoing engagement, education, and surveys—giving sponsors reliable data on attitudes, barriers, and readiness for participation.

Unmatched cultural credibility

Built through trusted partnerships, community leadership, and culturally relevant engagement that earns trust where traditional outreach cannot.

A first-of-its-kind pipeline into representative data

A continuous flow of lived-experience insights and community engagement that helps sponsors reduce enrollment risk and design more inclusive studies.

Customer Success Stories

Trusted Voices, Proven Impact

MMR

Fostering Health Equity in Multiple Myeloma Research

Multiple myeloma is the most common hematologic malignancy among Black & African Americans.1 However, they comprise only 4% of enrollees in clinical trials supporting FDA approval of multiple myeloma drugs.2 Acclinate collaborated with the Multiple Myeloma Research Foundation (MMRF) from April to October 2024 to address this disparity and support more representative research.
Read Case Study
83%-95%
of attendees felt comfortable participating in discussions about their health
9.6%-62%
reported limited knowledge of clinical trials before the events
32.3%-83%
felt more informed about clinical research after these events

Ready to Access the Most Trusted Community in Research?

Our community provides the foundational trust necessary to succeed in diverse clinical research.